GFAFX
Price
$85.30
Change
-$1.37 (-1.58%)
Updated
Jul 13 closing price
Net Assets
356.86B
PBQAX
Price
$28.11
Change
-$0.01 (-0.04%)
Updated
Jul 10 closing price
Net Assets
1.18B
Interact to see
Advertisement

GFAFX vs PBQAX

GFAFX vs PBQAX Comparison Chart in %
View a ticker or compare two or three
VS
GFAFX vs. PBQAX commentary
Jul 14, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GFAFX is a Buy and PBQAX is a StrongBuy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
GFAFX has more cash in the bank: 357B vs. PBQAX (1.18B). GFAFX pays higher dividends than PBQAX: GFAFX (0.20) vs PBQAX (0.04). GFAFX was incepted earlier than PBQAX: GFAFX (25 years) vs PBQAX (36 years). PBQAX (0.91) is less costly to investors than GFAFX (0.65). PBQAX is a more actively managed with annual turnover of: 59.00 vs. GFAFX (32.00). GFAFX has a lower initial minimum investment than PBQAX: GFAFX (250) vs PBQAX (1000). PBQAX annual gain was more profitable for investors over the last year : 12.94 vs. GFAFX (4.25). GFAFX return over 5 years is better than : 15.72 vs. PBQAX (3.55).
GFAFXPBQAXGFAFX / PBQAX
Total Expense Ratio0.650.9171%
Annual Report Gross Expense Ratio0.650.9171%
Fund Existence25 years36 years-
Gain YTD7.13413.80652%
Front LoadN/A6%-
Min. Initial Investment250100025%
Min. Initial Investment IRAN/AN/A-
Net Assets357B1.18B30,280%
Annual Yield % from dividends0.200.04570%
Returns for 1 year4.2512.9433%
Returns for 3 years39.1532.57120%
Returns for 5 years15.723.55443%
Returns for 10 years102.4552.28196%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FSEIX63.23N/A
N/A
Nuveen Mid Cap Value Opportunities I
FIKCX72.53N/A
N/A
Fidelity Advisor Health Care Z
VADGX32.27N/A
N/A
Vanguard Advice Select Dividend Gr Admrl
FBPGX29.15N/A
N/A
Cantor Fitzgerald Equity Dividend Plus A
PAMCX94.34N/A
N/A
T. Rowe Price Mid-Cap Growth Adv